Compare KLA Corp. (KLAC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs TransMedics Group Inc — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: KLA Corp. is far larger — about 93.7× TransMedics Group Inc's market cap, and KLA Corp. pays a 0.47% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and TransMedics Group Inc for 24 Days on average.
| KLAC | TMDX | |
|---|---|---|
Market Cap | $256.72B | $2.74B |
Volume | 9,970,753 | 949,331 |
Sector | Technology | Health |
52-Week High | $301.71 | $150.42 |
52-Week Low | $98.28 | $61.99 |
Typical Hold Time | 60 Days | 24 Days |
Enterprise Value | $257.97B | $3.13B |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing minimal daily movement with strong fundamental performance. The stock maintains bullish technical signals with support at $193 and resistance at $201. Recent earnings consistently beat expectations, with Q2 2026 EPS of $1.05 exceeding the $1.00 forecast. The company demonstrates robust profitability with 35.57% net income margin and 87.5% ROE, supported by AI-driven semiconductor equipment demand and a $12.57 billion backlog.
Outlook remains positive with analyst consensus target of $223.88 offering 14% upside potential. Key opportunities include AI infrastructure growth and advanced packaging demand, while risks involve competitive pressure from Applied Materials and ASML, along with execution challenges in meeting ambitious $26 billion revenue target by 2030. Institutional ownership trends show continued confidence with recent acquisitions by Envestnet Portfolio Solutions.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
